- The folks at University of Virginia are studying the effects of 9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC on Breast Cancer in individuals ages 18 years and older. This clinical trial is slated to start July 2012.434-982-1902 Emily Allred, PhD
|Recruiting||Emily Allred, PhD||EH4M@virginia.edu||434-982-1902|
This study is officially titled, "A Pilot Study of the Immunogenicity of a 9-Peptide Breast Cancer Vaccine Plus Poly-ICLC in Stage IB-IIIA Breast Cancer."
|Recruiting||University of Virginia Health System|
Charlottesville, Virginia, 22908
United States - map
For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.